ReviewThe Journal of dermatology2024
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.
Review in The Journal of dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature.Skin health and disease · 2026Article
- The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy.Dermatopathology (Basel, Switzerland) · 2026Review
- Management of Hidradenitis Suppurativa in Special Populations: A Narrative Review.Dermatology and therapy · 2025Review
- Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.Current gastroenterology reports · 2025Review
- Inflammatory Skin Diseases: The Importance of Immunological Signatures.Deutsches Arzteblatt international · 2025Review
- Disrupted Redox Regulation and Inflammatory Response in Pyoderma Gangrenosum.Life (Basel, Switzerland) · 2025Article
- A Case of Pyoderma Gangrenosum on the Lip.Clinical case reports · 2025Article
- Guselkumab - In Psoriasis and Beyond.Dermatology practical & conceptual · 2024Review
- The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.International journal of molecular sciences · 2024Review
- New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.The Journal of dermatology · 2024Review
- Concurrent Hidradenitis Suppurativa and Pyoderma Gangrenosum in a Pediatric Cohort: A Retrospective Case Series.Journal of cutaneous medicine and surgeryArticle
- Development of Pyoderma Gangrenosum in a Patient with Acquired Reactive Perforating Collagenosis.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are stubborn inflammatory skin diseases categorized as neutrophilic hypodermal dermatoses. These conditions exhibit connections with other autoinflammatory disorders driven by immune responses. Their pathogenesis is complex, rooted in significant imbalances in both innate and adaptive immune systems, particularly featuring elevated levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-8, IL-17, and IL-23. Studies involving skin tissue pathology and serology have indicated that targeting specific cytokines can bring therapeutic benefits. Indeed, many patients in clinical settings have responded positively to such interventions. Yet, given the diverse cytokines in play, focusing on a single one with antibody therapy might not always be effective. When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.